The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression

Atherosclerosis

Volumn 157, Issue 1, 2001, Pages 97-105

  Bocan, Thomas M A ^a   Krause, Brian R ^a   Rosebury, Wendy S ^a   Lu, Xiaokang ^a   Dagle, Catherine ^a   Bak Mueller, Sandra ^a   Auerbach, Bruce ^a   Sliskovic, D Robert ^a  

^a PFIZER INC   (United States)

Author keywords

ACAT; Antiatherosclerosis; Avasimibe; Lesion regression; Reductase; Simvastatin

Indexed keywords

ARACHIS OIL; AVASIMIBE; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; COCONUT OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE;

ACETATES; ANIMALS; ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; COENZYME A-TRANSFERASES; DRUG THERAPY, COMBINATION; HYDROXYMETHYLGLUTARYL COA REDUCTASES; RABBITS; SIMVASTATIN; SULFONIC ACIDS;

EID: 0034971344     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00713-9     Document Type: Article

References (42)

1. ACAT inhibitors: Physiologic mechanisms for hypolipidemic and anti-atherosclerotic activities in experimental animals
2. Emerging therapies in atherosclerosis
3. ACAT inhibitors: Evolution from cholesterol-absorption inhibitors to antiatherosclerotic agents
4. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits
5. Comparison of CI-976, an ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions: A biochemical, morphological and morphometric evaluation
6. HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits
7. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: A biochemical and morphological evaluation
8. Influence of mevinolin on experimental atherosclerosis in rabbits
9. Preventive effect of MK-733 (Simvastatin), an inhibitor of HMG-CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits
10. Effect of lovastatin on suppression and regression of atherosclerosis in lipid-fed rabbits
11. Suppression of established atherosclerosis and xanthomas in mature WHHL rabbits by keeping their serum cholesterol levels extremely low. Effect of pravastatin sodium in combination with cholestyramine
12. Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes
13. Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W6228) on migration, proliferation and cholesterol synthesis in arterial myocytes
14. Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733)
15. Production of advanced cholesterol atherosclerosis in the rabbit
16. Production of experimental atherosclerosis in animals
17. Inhibitors of acyl-CoA:cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: An acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets
18. Substituted malonester amides: Tools to define the relationship between ACAT inhibition and adrenal toxicity
19. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin
20. Enzymatic determination of total serum cholesterol
21. Quantitative determination of serum triglycerides by the use of enzymes
22. Rapid on-line determination of cholesterol distribution among plasma lipoproteins after high-performance gel filtration chromatography
23. Distribution and composition of ultracentrifugally separated lipoproteins in human sera
24. Protein measurements with the Folin phenol reagent
25. A simple method for the isolation and purification of total lipids from animal tissue
26. Rapid separation and quantitation of combined neutral and polar lipid classes by high-performance liquid chromatography and evaporative light-scattering mass detection
27. Immunocytochemical analysis of cellular components in atherosclerotic lesions. Use of monoclonal antibodies with the Watanabe and fat-fed rabbit
28. A smooth muscle-specific monoclonal antibody recognizes smooth muscle actin isozymes
29. Lipoprotein metabolism in the macrophage: Implications for cholesterol deposition in atherosclerosis
30. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry
31. Lipid in the aortic intima: The correlation of morphological and chemical characteristics
32. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages
33. Vastatins inhibit cholesterol ester accumulation in human monocyte-derived macrophages
34. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis
35. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
36. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
37. Hepatocyte selectivity of HMG-CoA reductase inhibitors
38. Effects of intracellular free cholesterol accumulation on macrophage viability. A model of foam cell death
39. Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells